The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition

Masafumi Inokuchi1 · Goro Kutomi2 · Yuko Kijima3 · Takehiko Sakai4 · Masataka Sawaki5 · Tadahiko Shien6 · Noriko Hanamura7 · Kenji Yano8 · Noriaki Wada9 · Shigehira Saji10 · Hiroji Iwata5

Received: 3 September 2019 / Accepted: 28 November 2019 / Published online: 12 December 2019
© The Author(s) 2019, corrected publication 2021

Abstract
We have prepared the Japanese Breast Cancer Society clinical practice guidelines (CPGs) for surgical treatment of breast cancer, 2018 update after a systematic review (SR) of the literature based upon the Medical Information Network Distribution Service (Minds) procedure. The CPG committee for surgical treatment of breast cancer, composed of breast surgeons and plastic surgeons treating breast cancer, has developed the CPGs. Eight clinical questions (CQs) were selected and divided roughly into the following five categories: (1) breast surgery in initial therapy (CQs 1–3); (2) axillary surgery in initial therapy (CQs 4–5); (3) breast reconstruction in initial therapy (CQ 6); (4) surgical treatment for recurrent and metastatic breast cancer (CQs 7–8); and (5) others. Recommendations for these CQs were decided by the GRADE grid method. In addition, 4 outlines, 14 background questions (BQs), and 12 future research questions (FQs) were also selected. Statements for these BQs and FQs are provided. We developed the updated CPGs for surgical treatment of breast cancer, 2018, which include 8 CQs and recommendations. As a decision-making tool for the understanding and treatment of breast cancer, these guidelines will help surgical oncologists dealing with breast cancer, medical staff, and patients, along with their family members.

Keywords Clinical practice guideline · Clinical question · Surgical treatment of breast cancer

Introduction
In the Breast Cancer Practice Guidelines, 2018 edition, guidelines were developed while weighing the balance of benefits and harms, and the Medical Information Network Distribution Service (Minds) Handbook for Clinical Practice Guideline Development 2014 [1] was used as a reference. In contrast to the method of the previous guidelines, we conducted a systematic review (SR) for each clinical question (CQ) and decided on the recommendations. In preparing clinical practice guidelines (CPGs), the CPG subcommittee for surgical treatment of breast cancer, composed of breast surgeons and plastic surgeons treating breast cancer, worked over a period of about one and a half years.
Initially, we created scopes in five categories that were significant clinical problems in surgery: (1) breast surgery in initial therapy; (2) axillary surgery in initial therapy; (3) breast reconstruction in initial therapy; (4) surgical treatment for recurrent and metastatic breast cancer; and (5) others. While further checking the CQs of the last, 2015 edition [2], we developed the 9 CQs for this 2018 edition. The process for CQs was: (1) setting of outcomes; (2) collecting evidence; (3) primary screening; (4) secondary screening; (5) evaluation of each article; (6) evaluation of the strength of the evidence; (7) integration of the evidence; (8) creation of recommendations; (9) recommendation decision meeting; (10) writing of the commentary; (11) evaluation by the Evaluation Committee; and (12) board approval and its final decision.

Furthermore, we created background questions (BQs) and future research questions (FQs). Background questions (BQs) were positioned as standard treatments in previous guidelines for each important clinical subject. Future research questions (FQs), which are currently insufficiently researched but may be taken up as CQs in the future, were also organized and set up among the CQs of the 2015 edition [2] with added statements and commentary. Table 1 shows the structure of the guidelines for surgical treatment.

For this edition, we developed 8 CQs and 14 BQs. There is one new CQ (CQ1), and we selected the other seven CQs from the CQs of the 2015 edition. In this article, we introduce the contents of the CQs and BQs.

### Clinical questions and recommendations

* Structure: CQ sentence, recommendation, strength of recommendation (Table 2 shows recommendation grades.), and strength of evidence. (Table 3 shows strength of evidence.)

| Table 1 Scope and structure of the guidelines for surgical treatment |
|-------------------------------------------------|
| (1) Breast surgery in initial therapy | Outline, BQ 1–3, CQ 1–3, FQ 1 |
| (2) Axillary surgery in initial therapy | Outline, BQ 4–9, CQ 4–5, FQ 2–4 |
| (3) Breast reconstruction in initial therapy | Outline, BQ 10, CQ 6, FQ 5 |
| (4) Surgical treatment for recurrent and metastatic breast cancer | Outline, CQ7–8, FQ 6–10 |
| (5) Others | BQ 11–14, FQ 11–12 |

**Table 2 Recommendation grade**

| Strength of recommendation | Statement | Clinical meaning |
|----------------------------|-----------|------------------|
| 1 | Strongly recommend to do | It is possible to paraphrase you should examine |
| 2 | Weekly recommend to do | If anything recommends to do based on considering balance between harm and benefit, patient’s values |
| 3 | Weekly recommend to not to do | If anything recommends to not to do based on considering balance between harm and benefit, patient’s values |
| 4 | Strongly recommend to not to do | You should not examine because of CQ which extremely exceed harm than benefit |

**Table 3 Strength of evidence**

| Strength | Example |
|----------|---------|
| Strong | Several high-quality studies with consistent results |
| Moderate | One high-quality study |
| Weak | Studies with severe limitations |
| Very weak | Studies with very severe limitations or expert opinion |

**Breast surgery in the initial treatment of breast cancer**

**CQ1:** Is surgery recommended for patients with non-invasive ductal cancer (ductal carcinoma in situ: DCIS)?

(Recommendation) Surgery for patients with non-invasive ductal carcinoma is weakly recommended. [Strength of recommendation (SoR): 3, strength of evidence (SoE): very weak]

**CQ2:** In breast-conserving surgery (BCS) for invasive/non-invasive ductal carcinoma, is additional surgery recommended for patients with positive surgical margins?

(Recommendation) Additional surgery is weakly recommended for patients with positive surgical margins in BCS. (SoR: 2, SoE: weak)

**CQ3:** Is skin-sparing or nipple/areola-sparing mastectomy recommended in breast reconstruction?

**CQ3a:** Is skin-sparing mastectomy (SSM) recommended?

(Recommendation) Skin-sparing mastectomy is weakly recommended. (SoR: 2, SoE: weak)

**CQ3b:** Is nipple-sparing mastectomy (NSM) recommended?
Nipple-sparing mastectomy is weakly recommended. (SoR: 2, SoE: weak)

Axillary surgery in the initial treatment of breast cancer

CQ4: Is no further axillary surgery for patients with sentinel node metastasis recommended?
   CQ4a: In cases of micrometastases
      (Recommendation) Is no further axillary surgery is strongly recommended. (SoR: 1, SoE: moderate)
   CQ4b: In cases of macrometastases
      (Recommendation) Is no further axillary surgery is weakly recommended. (SoR: 2, SoE: weak)
      CQ4b-1: Breast-conserving therapy
         (Recommendation) Further axillary surgery is strongly recommended. (SoR: 4, SoE: very weak)
      CQ4b-2: Total mastectomy (without radiation therapy)
         (Recommendation) Is no further axillary surgery is weakly recommended. (SoR: 2, SoE: weak)
      CQ4b-3: Total mastectomy (with radiation therapy)
         (Recommendation) Is no further axillary surgery is weakly recommended. (SoR: 2, SoE: weak)

CQ5: Is sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) recommended for avoidance of ALND?
   CQ5a: Is SLNB for clinical node-negative breast cancer before and after NAC recommended?
      (Recommendation) SLNB is weakly recommended. (SoR: 2, SoE: weak)
   CQ5b: Is SLNB recommended, if an ipsilateral axillary lymph node is initially positive, and it is clinically negative after NAC?
      (Recommendation) It is weakly recommended not to perform SLNB (recommended to perform ALND) (SoR: 3, SoE: weak)

Breast surgery in the initial treatment of breast cancer

BQ1: Is breast-conserving therapy (BCT) recommended for ductal carcinoma in situ (DCIS)?
   (Statement) BCT for DCIS is performed according to the indication for BCT for invasive breast cancer.

BQ2: Is BCT recommended as a local therapy for stage I and II invasive breast cancer?
   (Statement) As a local treatment for stage I and II breast cancer, BCT is regarded as the first choice if indicated, because it provides a survival equivalent to mastectomy.

BQ3: Is BCT recommended for invasive breast cancer patients responding to neoadjuvant chemotherapy (NAC)?
   (Statement) BCT is recommended for invasive breast cancer patients responding to NAC.

Axillary surgery in the initial treatment of breast cancer

BQ4: Is level I and II ALND recommended for patients with clinically positive axillary lymph nodes?
   (Statement) Level I and II ALND is recommended for patients with clinically positive axillary lymph nodes.

BQ5: Is no further axillary surgery for clinically node-negative breast cancer patients without SLN metastases recommended?
   (Statement) No further axillary surgery for women with clinically axillary node-negative breast cancer who do not have nodal metastases by SLNB is the standard treatment.
BQ6: Is SLNB with a combination of blue dye and radioisotope (RI) recommended?

(Statement) The combination of blue dye and RI showed slightly better identification rates than either method used alone; therefore the combined method is standard, but the single methods are also acceptable.

BQ7: Is SLNB recommended for patients with an initial diagnosis of DCIS?

(Statements) SLNB should not be performed for patients for scheduled breast-conserving therapy when the postoperative pathological diagnosis is considered to be DCIS.
- If it is difficult to perform SLNB at a later time, SLNB together with primary tumor resection is acceptable.

BQ8: Is upper limb rehabilitation recommended after ALND?

(Statement) Upper limb rehabilitation should be performed after ALND.

BQ9: Is prevention and treatment of ipsilateral postoperative upper limb lymphedema for breast cancer patients recommended?

(Statements)
① Prevention:
Appropriate preventive education (skin care) and exercise therapy for postoperative lymphedema reduce the incidence rate and increase the opportunity for early intervention at onset. There are no data that clearly show the preventive effects of manual self-lymph drainage performed by patients and families on upper limb lymphedema.
② Treatment:
Combined treatment based on compression therapy using elastic garments and bandages and exercise under compression is effective regardless of the stage of upper limb lymphedema.

Breast reconstruction in the initial treatment of breast cancer

BQ10: Is breast reconstruction recommended for patients with a history of chest wall irradiation?

(Statement) Breast implant-based reconstruction is not encouraged.
Breast reconstruction using autologous tissue is possible.

Others

BQ11: Is surgery recommended for pregnant patients with breast cancer?

(Statement) Surgery is recommended even for pregnant patients with breast cancer.

BQ12: Is surgery recommended for elderly women with breast cancer?

(Statement) Surgery is also the standard treatment for elderly women with breast cancer if they are healthy enough to tolerate surgery.

BQ13: Is routine use of antibiotic prophylaxis for breast cancer surgery recommended?

(Statement) Prophylactic antibiotics should be given during breast cancer surgery.

BQ14: Is surgery recommended for phyllodes tumor?

(Statements) The standard treatment for patients with a pathological diagnosis of phyllodes tumor is complete surgical resection. Taking into account the size and grade of the tumor, it can be necessary to have wide local excision with appropriate margins.

Conclusion

This time, for eight CQs in the clinical practice guidelines, 2018 edition, SR was performed to determine the recommendations. It is hoped that these guidelines can be used as a tool for physicians and patients in shared decision-making when deciding on breast cancer treatment.

Acknowledgements

The authors are grateful to Ms. Yayoi Adachi, Ms. Yumi Kashikura, Mr. Hiroaki Shima, Mr. Takahiro Tsukikoki, and Ms. Kazuyo Yoshida for their essential help with the systematic review. The authors would also like to thank Fujimi Kawai of the Japanese Medical Library Society and Prof. Masahiro Yoshida of International University of Health and Welfare for their generous advice. They also thanks Kanehara Publishing Co., Ltd. Hitomi Sasaki and Kazuyo Uno.

Funding  None.

Compliance with ethical standards

Conflict of interest  M Inokuchi, G. Kutomi, Y. Kijima, T. Sakai, M. Sawaki, T. Shien, N. Hanamura, K. Yano, and N. Wada have no conflicts of interest. S. Saji reports grants and personal fees (honoraria for lectures) from Eisai, grants and personal fees from Chugai, grants and personal fees from AstraZeneca, grants and personal fees from Takeo, grants and personal fees from Novartis, grants and personal fees from Taiho, personal fees from Kyowa Hakko Kirin, personal fees from Pfizer, personal fees from Daiichi Sankyo, grants and personal fees from Nihon Kayaku, grants from Ono, outside the submitted work; S. Saji is executive board member of Japan Breast cancer Research Group (JBCRG) and Japanese Breast Cancer Society (JBCS). H. Iwata reports grants and personal fees from Chugai, personal fees from AstraZeneca, personal fees from Daiichi Sankyo, grants and personal fees from Novartis, grants and personal fees from Lilly, personal fees from Kyowa Hakko Kirin, personal fees from Pfizer, during the conduct of the study; However, H. Iwata confirm total fee from each company is not over the limited fee determined by JBCS. H. Iwata is executive board member of JBCS.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Morizane T, Yoshida, M, Kojimahara N. Minds Handbook for clinical practice guideline development 2014. 2014.
2. Jinno H, Inokuchi M, Ito T, Kitamura K, Kutomi G, Sakai T, et al. The Japanese Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer, 2015 edition. Breast Cancer. 2016;23:367–77.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.